Open Orphan Plc

ORPH.LN

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands. Open Orphan is led by a management team with deep industry and financial experience.

Related content

Latest Analysis |

Open Orphan surges thanks to first mover advantage in infectious disease

Open Orphan offers considerable first mover advantage in the fight against infectious diseases.

Latest Analysis |

Open Orphan hails “transformation” as results deliver on promises

Open Orphan is making headlines as the Covid-19 pandemic highlights the importance of its work in the infectious diseases space.

Latest Analysis |

Open Orphan branches out amid infectious disease gold rush

A new wave of research into malaria treatments has kicked off over the last 18 months. Which is great news for clinical research organisation Open...

Latest Analysis |

Near-term profitability, spin outs, and challenge study contracts put Open Orphan on track for major valuation growth (ORPH)

After years of hard work, pharmaceutical services firm Open Orphan is reporting ongoing profitability.

Press Releases |

Open Orphan expands human challenge trial capacity with new volunteer recruitment centres

Press Releases |

Open Orphan and hVIVO’s human vaccine trial for Covid-19 begins

Press Releases |

Open Orphan has a great start to 2021 with key 12-month contract renewal

Press Releases |

Open Orphan wins vaccine contract extension and announces toxicology study completion

Press Releases |

“We are scaling-up rapidly and at minimum expense” – Open Orphan’s Cathal Friel on the pharma services firm’s exciting plans for 2021 and beyond

Press Releases |

Open Orphan and Codagenix receive MHRA approval for Covid vaccine challenge study

Press Releases |

Open Orphan continues to convert deal pipeline with key Venn contracts

Press Releases |

Open Orphan strengthens board with Elaine Sullivan hire

Press Releases |

Open Orphan leads weighty Wellcome Trust bid to define human challenge drug standards

Latest Analysis |

The Second-Gen Covid-19 Stocks Offering Explosive Opportunities

The Covid-19 pandemic will not end with a silver-bullet vaccine. We already know this, so wise traders are instead looking to the companies that do...

Press Releases |

Open Orphan lands another £2.5m flu challenge study contract

Press Releases |

Open Orphan extends pharmacometrics relationship with tier 1 German pharma company

Sign up for VTM Updates

Form submitted successfully!

VTM Exclusive Reports

Crypto Corner

Learn your NFTs from your BTCs